Hissar Syed S, Kumar Manoj, Tyagi Pankaj, Goyal Ankur, Suneetha P V, Agarwal Sriram, Rastogi Archana, Sakhuja Puja, Sarin Shiv K
Department of Gastroenterology, G.B. Pant Hospital, New Dehli 110002, India.
J Gastroenterol Hepatol. 2009 Apr;24(4):581-7. doi: 10.1111/j.1440-1746.2008.05649.x. Epub 2008 Nov 20.
The rate of fibrosis progression per year can predict the time for the development of cirrhosis in chronic hepatitis C (CHC). We assessed the rate of fibrosis progression and the predictors of disease severity in Indian CHC patients.
Of the 355 treatment-naïve, histologically-proven CHC patients, the precise duration of infection (from the time of exposure to HCV until liver biopsy) could be determined in 213 patients (age = 41.6 +/- 14.7 years, male : female = 139 : 74, genotype 3 = 75%). The rate of fibrosis progression per year was calculated. The correlation of the advanced degree of fibrosis and age, duration of infection, age at the onset of infection, sex, mode of infection, hepatitis C virus (HCV) genotype, histological activity index (HAI), and the presence of diabetes mellitus were studied.
The median rate of fibrosis progression per year was 0.25 (0.0-1.5) fibrosis units. The fibrosis progression rate was higher in patients who acquired infection at > 30 years of age, those < 30 years (0.33 vs 0.15; P < 0.001), and those who acquired HCV infection with a history of blood transfusion than with other modes of transmission (0.25 vs 0.19; P = 0.04). The median time to progress to cirrhosis was 16 years. The multivariate analysis found that the HAI score (odds ratio [OR]= 14.03; P < 0.001) and the duration of infection > 10 years (OR = 4.83; P < 0.001) correlated with severe liver disease (fibrosis > or = 3).
The median rate of fibrosis progression per year in Indian CHC patients is 0.25 fibrosis units. A higher HAI and longer duration of infection are associated with a significant risk of advanced liver disease, and merit early therapeutic interventions.
每年的纤维化进展速率可预测慢性丙型肝炎(CHC)患者发生肝硬化的时间。我们评估了印度CHC患者的纤维化进展速率及疾病严重程度的预测因素。
在355例未经治疗、经组织学证实的CHC患者中,213例患者(年龄=41.6±14.7岁,男∶女=139∶74,基因3型=75%)能够确定确切的感染持续时间(从接触丙型肝炎病毒[HCV]至肝活检的时间)。计算每年的纤维化进展速率。研究纤维化的进展程度与年龄、感染持续时间、感染起始年龄、性别、感染方式、HCV基因分型、组织学活动指数(HAI)及糖尿病的存在之间的相关性。
每年纤维化进展的中位数速率为0.25(0.0~1.5)个纤维化单位。30岁以上感染患者的纤维化进展速率高于30岁以下患者(0.33对0.15;P<0.001),有输血史感染HCV的患者比通过其他传播方式感染的患者纤维化进展速率更高(0.25对0.19;P=0.04)。进展至肝硬化的中位时间为16年。多因素分析发现,HAI评分(比值比[OR]=14.03;P<0.001)及感染持续时间>10年(OR=4.83;P<0.001)与严重肝病(纤维化≥3期)相关。
印度CHC患者每年纤维化进展的中位数速率为0.25个纤维化单位。较高的HAI评分及较长的感染持续时间与晚期肝病的显著风险相关,值得早期进行治疗干预。